NasdaqCM - Nasdaq Real Time Price USD

MiNK Therapeutics, Inc. (INKT)

0.9275 +0.0563 (+6.46%)
At close: April 26 at 4:00 PM EDT
0.9748 +0.05 (+5.10%)
After hours: April 26 at 7:22 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Garo H. Armen Ph.D. Executive Chairman -- -- 1953
Dr. Jennifer S. Buell Ph.D. President, CEO & Director 812.78k -- 1976
Dr. Marcus Antonius van Dijk Ph.D. Chief Scientific Officer 369.92k -- 1962
Ms. Christine M. Klaskin Treasurer 27.24k -- 1966
Joy Zhou Ph.D. Vice President & Head of CMC -- -- --

MiNK Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8250 https://minktherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
31

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Corporate Governance

MiNK Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 11, 2024 - May 15, 2024
MiNK Therapeutics, Inc. Earnings Call

Related Tickers

AGEN Agenus Inc.
11.69
+40.84%
 
PTIX Protagenic Therapeutics, Inc.
1.3850
-4.48%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
AKTX Akari Therapeutics, Plc
1.1850
+1.28%
 
LIXT Lixte Biotechnology Holdings, Inc.
3.2600
+0.31%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
MBIO Mustang Bio, Inc.
0.3161
-11.58%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%